Lincoln Pharmaceuticals achieves the milestone of Profit Growth Every Single year from FY13 to FY23

Ahmedabad, Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has achieved the milestone of reporting a profit growth every single year from FY13 to FY23. It is among only 16 companies out of 4,200 plus listed companies in the Indian stock exchange to do so as per the analysis of Morningstar.

During 10 years from FY13 to FY23, Company has delivered a robust CAGR of over 22% in Net profits, 19% plus in EBITDA and over 10% in Revenue. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no-term debt, and healthy return ratios.

Backed by improvement in the company’s financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.

For FY23, company has reported its Best-ever results in a financial year with highest – Revenue, EBITDA and Net Profit. Company achieved a milestone of Rs. 500 crore plus revenue and Rs. 100 crore plus profit before tax for the first time in a financial year.

Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We are very happy and excited to know that Lincoln Pharma has been able to achieve profit growth every single year over the last 10 years and among a very few companies to do so.

Company is growing from strength-to-strength over the years and expects to maintain the growth in years to come. Strategic growth initiatives, product and geographical expansion, and operational efficiency are likely to contribute to growth going forward. Company has set a target of achieving Rs. 750 crore revenue by FY26 while maintaining or improving its margins. ”